# PL BioScience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pl-bioscience

- Industry: Biotechnology
- Headquarters: Aachen, Germany
- Website: www.pl-bioscience.com
- Total disclosed funding: $13M
- Latest round: Series A (Apr 9, 2024)
- Investors on record: 9

## About

Based in Germany, PL BioScience GmbH focuses on developing and commercializing Human Platelet Lysate (HPL) products for academic research, diagnostics, and regenerative medicine, emphasizing ethical and high-quality cell culture solutions.Founded in 2015 and headquartered in Aachen, Germany, PL BioScience GmbH specializes in Human Platelet Lysate (HPL) products. The company has completed five deals, with its most recent funding round being a Series A in April 2024, raising EUR 7.8 million from investors including TechVision and Brightlands Venture. CEO Hatim Hemeda and co-founder Christian Wilkes bring experience from their previous ventures to this innovative company.PL BioScience GmbH specializes in the development and commercialization of Human Platelet Lysate (HPL) products under the brand name ELAREM™, which includes offerings such as ELAREM™ Prime, ELAREM™ Perform, and ELAREM™ Ultimate. These products are designed for academic research, diagnostics, and regenerative medicine, providing xeno-free alternatives to traditional cell culture supplements. Targeting clients in Europe, North America, and Asia, they aim to advance cell-based research and therapies with ethically sourced culture media solutions.The revenue model of PL BioScience centers on the direct sales of its ELAREM™ product line, including specialized Research Grade, GMP Grade, and GMP-Clinical Grade formulations. These products cater to specific safety and regulatory needs, with clients placing B2B orders based on their research requirements. Long-term purchasing agreements often establish ongoing supply relationships, particularly in the academic and clinical research sectors, reflecting the company's role in the regenerative medicine landscape.In April 2024, PL BioScience GmbH secured EUR 7.8 million in Series A funding to enhance its manufacturing capabilities and strengthen its position in the international cell culture sector. The funding will support the development of upcoming products, including new formulations aimed at expanding their market reach. The company is looking to target additional markets in Asia and North America by 2025, aiming to leverage its innovative HPL solutions in these regions.

## Funding rounds

- Series A, Apr 9, 2024, $8.5M — Brightlands Venture Partners, TechVision Fonds, b.value, D11Z.Ventures, GoodFace Capital, Rettenstein GmbH, CITO, 7cap Investments GmbH
- Series A, Apr 28, 2021, $4.5M — Brightlands Venture Partners, SilverSky

## Investors

- Brightlands Venture Partners (https://capitalatlas.ai/funds/brightlands-venture-partners) — Series A
- SilverSky — Series A
- TechVision Fonds (https://capitalatlas.ai/funds/techvision-fonds) — Series A
- b.value (https://capitalatlas.ai/funds/b-value) — Series A
- D11Z.Ventures (https://capitalatlas.ai/funds/d11z-ventures) — Series A
- GoodFace Capital (https://capitalatlas.ai/funds/goodface-capital) — Series A
- Rettenstein GmbH — Series A
- CITO (https://capitalatlas.ai/funds/cito) — Series A
- 7cap Investments GmbH — Series A